Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder
The DOI matches its Crossref record, with a small difference in title or year; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor family of neurotrophins, has pivotal roles in neuronal survival, proliferation, and synaptic plasticity in the brain. Both clinical and pharmacological studies have implicated the common single nucleotide polymorphism (SNP) at position 196, Val66Met in the pathophysiology of major depressive disorder (MDD), and antidepressant response. However, inconsistent results were found between Val66Met (rs6265) polymorphism and treatment response phenotypes in genetic association studies. The functional Val66Met polymorphism and seven other tagging SNP markers selected to capture the major allelic variations across BDNF locus were analyzed in depressed patients, treated with antidepressants, and 76 control patients. Two hundred and six patients with Diagnostic and Statistical Manual of Mental Disorders-IV MDD were recruited for this study and genotyped for eight BDNF tagging SNPs (rs11030096, rs925946, rs10501087,rs6265, rs12273363, rs908867, rs1491850, and rs1491851)to investigate the functional impact of genotypes/haplotypes in the susceptibility of depression and on treatment response. None of the eight SNPs, including the rs6265, were significantly associated with MDD after permutation correction. However, we found an association for rs10501087, rs6265 with nonresponse to antidepressant treatment (corrected permutation P:0.03599; 0.0399 and power: 0.1420; 0.1492, respectively).Analysis of each two-marker, three-marker, and four-marker sliding window haplotypes showed significance in haplotype combinations. Especially rs10501087 (C), rs6265 (A), and rs149,1850 (C) together or with the other SNP haplotypes showed a similar pattern in all treatment response phenotypes. Despite the limited power of analysis, our results suggest that these three SNPs may play a role in antidepressant treatment response phenotypes in MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with major depressive disorder, the BDNF val66met SNP, as well as two other BDNF SNPs, were linked to a reduced response to antidepressant treatment suggesting that these SNPs may impact treatment responses to antidepressants (Kocabas et al., 2011).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Kocabas et al., 2011
Citations
Cites
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 7×
“Sequence variations in the BDNF gene, which may lead to variations in gene expression or protein metabolism have been advanced as possible causes of selective neuronal vulnerability (Egan et al., 2003).”
BackgroundInfluentialThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 12×
“these effects are both region-specific and antidepressantspecific (Krishnan and Nestler, 2008).”
BackgroundInfluentialEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045 · cited 1×
“Recent human studies have indicated that Val66Met polymorphism has an impact on episodic memory, hippocampal morphology, and memory-related hippocampal activity (Egan et al., 2003; Hariri et al., 2003; Hashimoto, 2007).”
BackgroundBrunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform
Gabriel, S., Ziaugra, L., & Tabbaa, D. (2009) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0212s60 · Cited by 969
Pruunsild, P., Kazantseva, A., Aid, T., Palm, K., & Timmusk, T. (2007) · Genomics · doi:10.1016/j.ygeno.2007.05.004 · Cited by 699 · cited 2×
“have been identified in all examined brain regions (Pruunsild et al., 2007).”
BackgroundWang, J.-W., David, D. J., Monckton, J. E., Battaglia, F., & Hen, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3632-07.2008 · Cited by 550
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 1×
“Detailed information on the diagnosis, recruiting method, and treatment response phenotypes of patients have been published by our group (Souery et al., 2007).”
MethodSelf-citationMcMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Laje, G., Fava, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 474
Verhagen, M., van der Meij, A., van Deurzen, P. A. M., Janzing, J. G. E., Arias-Vásquez, A., Buitelaar, J. K., & Franke, B. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.109 · Cited by 470 · cited 1×
“In two recent meta-analyses, no significant associations between Val66Met polymorphism and MDD were found (Chen et al., 2008; Verhafen et al., 2008).”
BackgroundFrodl, T., Schüle, C., Schmitt, G., Born, C., Baghai, T., Zill, P., Bottlender, R., Rupprecht, R., Bondy, B., Reiser, M., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.410 · Cited by 394
Adachi, M., Barrot, M., Autry, A. E., Theobald, D., & Monteggia, L. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.019 · Cited by 380
Sullivan, P. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.010 · Cited by 335
Variant BDNF (Val66Met) impact on brain structure and function
BATH, K. G., & LEE, F. S. (2006) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.6.1.79 · Cited by 330
Schumacher, J., Jamra, R. A., Becker, T., Ohlraun, S., Klopp, N., Binder, E. B., Schulze, T. G., Deschner, M., Schmäl, C., Höfels, S., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.006 · Cited by 309
Matrisciano, F., Bonaccorso, S., Ricciardi, A., Scaccianoce, S., Panaccione, I., Wang, L., Ruberto, A., Tatarelli, R., Nicoletti, F., Girardi, P., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.03.014 · Cited by 253
Shaking the tree: mapping complex disease genes with linkage disequilibrium
Palmer, L. J., & Cardon, L. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67485-5 · Cited by 234
Tsai, S., Cheng, C., Yu, Y. W., Chen, T., & Hong, C. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20026 · Cited by 214
Licinio, J., Dong, C., & Wong, M.-L. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.38 · Cited by 176
Kemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170 · cited 2×
“Response rates of little more than 50% are common for the treatment of depression (Reynolds, 2007; Kemp et al., 2008).”
BackgroundThe implications of gene–environment interactions in depression: will cause inform cure?
Uher, R. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.92 · Cited by 159
Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response
Domschke, K., Lawford, B. R., Laje, G., Berger, K., Young, R. M., Morris, C. P., Deckert, J., Arolt, V., McMahon, F. J., & Baune, B. T. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000030 · Cited by 134
Six Months of Treatment for Depression: Outcome and Predictors of the Course of Illness
Mulder, R. T., Joyce, P. R., Frampton, C. M. A., Luty, S. E., & Sullivan, P. F. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.95 · Cited by 127
Piccinni, A., Del Debbio, A., Medda, P., Bianchi, C., Roncaglia, I., Veltri, A., Zanello, S., Massimetti, E., Origlia, N., & Domenici, L. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.002 · Cited by 120
Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression
Anttila, S., Huuhka, K., Huuhka, M., Rontu, R., Hurme, M., Leinonen, E. V. J., & Lehtimäki, T. J. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0705-9 · Cited by 112
5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression
Bocchio‐Chiavetto, L., Miniussi, C., Zanardini, R., Gazzoli, A., Bignotti, S., Specchia, C., & Gennarelli, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.04.005 · Cited by 111
Genetic association study of BDNF in depression: Finding from two cohort studies and a meta‐analysis
Chen, L., Lawlor, D. A., Lewis, S. J., Yuan, W., Abdollahi, M. R., Timpson, N. J., Day, I. N. M., Ebrahim, S. B. J., Smith, G. D., & Shugart, Y. Y. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30686 · Cited by 101
BDNF Gene: Functional Val66Met Polymorphism in Mood Disorders and Schizophrenia
RYBAKOWSKI, J. K. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1589 · Cited by 96
Gratacòs, M., Soria, V., Urretavizcaya, M., González, J. R., Crespo, J. M., Bayés, M., de Cid, R., Menchón, J. M., Vallejo, J., & Estivill, X. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500460 · Cited by 95
Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes
Rybakowski, J. K., Suwalska, A., Skibinska, M., Dmitrzak‐Weglarz, M., Leszczynska‐Rodziewicz, A., & Hauser, J. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30420 · Cited by 91
BDNF variant linked to anxiety‐related behaviors
Hashimoto, K. (2007) · BioEssays · doi:10.1002/bies.20534 · Cited by 89
Hashimoto, R., Moriguchi, Y., Yamashita, F., Mori, T., Nemoto, K., Okada, T., Hori, H., Noguchi, H., Kunugi, H., & Ohnishi, T. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.04.003 · Cited by 87
Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression
Duncan, L. E., Hutchison, K. E., Carey, G., & Craighead, W. E. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.08.016 · Cited by 82
Gatt, J. M., Kuan, S. A., Dobson‐Stone, C., Paul, R. H., Joffe, R. T., Kemp, A. H., Gordon, E., Schofield, P. R., & Williams, L. M. (2008) · Biological Psychology · doi:10.1016/j.biopsycho.2008.07.004 · Cited by 76
Okada, T., Hashimoto, R., Numakawa, T., Iijima, Y., Kosuga, A., Tatsumi, M., Kamijima, K., Kato, T., & Kunugi, H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001822 · Cited by 76
BDNF in Anxiety and Depression
Kalueff, A. V., Avgustinovich, D. F., Kudryavtseva, N. N., & Murphy, D. L. (2006) · Science · doi:10.1126/science.312.5780.1598 · Cited by 72
Oswald, P., Del‐Favero, J., Massat, I., Souery, D., Claes, S. J., Broeckhoven, C. V., & Mendlewicz, J. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30056 · Cited by 67
Self-citationThe When and Where of BDNF and the Antidepressant Response
Wang, J., Dranovsky, A., & Hen, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.008 · Cited by 59
The impact of pharmacogenetics on the development and use of antipsychotic drugs
Reynolds, G. P. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.018 · Cited by 41
Oswald, P., Del‐Favero, J., Massat, I., Souery, D., Claes, S. J., Broeckhoven, C. V., & Mendlewicz, J. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.01.001 · Cited by 37
Self-citationThe pharmacogenetics of major depression: past, present, and future.
Laje, G., & Mcmahon, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.016 · Cited by 28
Wray, N. R., James, M. R., Handoko, H. Y., Dumenil, T. D., Lind, P. A., Montgomery, G. W., & Martin, N. G. (2008) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283050aee · Cited by 18
Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder
Luca, V. D., Strauss, J., Semeralul, M. O., Huang, S., Li, P. P., Warsh, J. J., Kennedy, J. L., & Wong, A. H. C. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.025 · Cited by 11
Pharmacogenetic Studies of Depression
Henn, F. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.008 · Cited by 4
Cited by
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“In patients with major depressive disorder, the BDNF val66met SNP, as well as two other BDNF SNPs, were linked to a reduced response to antidepressant treatment suggesting that these SNPs may impact treatment responses to antidepressants (Kocabas et al., 2011).”
BackgroundPharmacogenetics in major depression: A comprehensive meta-analysis
Niitsu, T., Fabbri, C., Bentini, F., & Serretti, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.011 · Cited by 190
“The excluded studies focused on the association between rs6265 and AD efficacy reported positive associations (Kocabas et al., 2011; Mandelli et al., 2010; Xu AC C EP TE D M AN U SC R IP T et al., 2012a; Zou et al., 2010a), or no association (Domschke et al., 2010; Huuhka et al., 2007).”
Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?
Porter, G. A., & O’Connor, J. C. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i1.77 · Cited by 178
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“Several SNPs in the BDNF gene, including the functional Val66Met polymorphisms rs6265, rs11030104 and rs11030101, may affect the risk of treatment resistance but not suicidality (Kocabas et al. 2011; Schosser et al. 2012b, 2017; Fabbri et al. 2014, 2017a).”
BackgroundSelf-citationSchosser, A., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., & Kasper, S. F. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.02.006 · Cited by 145
Self-citation
Metadata
- Authors
- Kocabas, N. A., Antonijevic, I., Faghel, C., Forray, C., Kasper, S., Lecrubier, Y., Linotte, S., Massat, I., Mendlewicz, J., Noro, M., Montgomery, S., Oswald, P., Snyder, L., Zohar, J., & Souery, D.
- Affiliations
- Lundbeck (United States) (US)
- Medical University of Vienna (AT)
- Inserm (FR)
- Fund for Scientific Research (BE)
- Université Libre de Bruxelles (BE)
- Imperial College London (GB)
- Sheba Medical Center (IL)
- ORCID
- Venue
- International Clinical Psychopharmacology
- Published
- 2011-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2079527591
- Cited by
- 74
- References
- 46
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 2 · 2019: 3 · 2017: 4 · 2016: 5 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 6
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Fonds De La Recherche Scientifique - FNRS
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brain-derived neurotrophic factor, BDNF gene polymorphism, major depressive disorder, antidepressant response, antidepressant non-response, BDNF Val66Met polymorphism, tagging SNPs, haplotypes, genetic susceptibility to depression, neurotrophins
- MeSH terms
- Alleles, Antidepressive Agents, Major Depressive Disorder, Female, Gene Frequency, Genotype, Haplotypes, Humans, Male, Middle Aged, Phenotype, Remission Induction, Treatment Outcome, Brain-Derived Neurotrophic Factor, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.